What would a Harris or Trump presidency mean for health care policy? Why did Eli Lilly’s Mounjaro and Zepbound sales miss expectations? And does Adam believe in ghosts?
We talk about all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Adam, Allison, and Elaine get into the Halloween spirit this week, discussing their favorite candies — and Eli Lilly and Pfizer’s surprise earnings reports. Then, they discuss what a Trump or Harris presidency could mean for health care and the biopharma industry, and what investors and biopharma executives think about either outcome.
For more on Eli Lilly’s surprise earnings miss, go here; to read how Pfizer beat expectations and responded to activist investor pressures, go here; for Adam’s column on Trump, RFK Jr. and biotech stocks, go here; to read how a second Trump administration could change health care, go here; and for more on how a Harris presidency could impact health care, go here.
Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, TuneIn, or wherever you get your podcasts.